Cassidy A. Pomeroy-Carter

CASSIDY POMEROY-CARTER focuses her practice on intellectual property and commercial transactions in the life sciences sector. She leverages her educational background in biology as well as her prior professional experience in science policy and consulting to think strategically about the transactions she supports.

Cassidy earned her J.D. from Stanford Law School, where she was actively involved in research, teaching, and clinical activities relating to intellectual property, life sciences, and bioethics. Prior to attending law school, Cassidy worked in science policy, providing technical and policy analysis to federal science-conducting agencies, including the White House Office of Science and Technology Policy, the National Institutes of Health, and the National Science Foundation. She also worked for an advising firm to provide technical, regulatory, and policy analysis to private sector clients in a variety of industries, ranging from food and agriculture to advanced manufacturing.

• Represented Alloy Therapeutics, in a strategic collaboration with Sanofi to develop an antisense oligonucleotide drug for a central nervous system target. Under the terms of the agreement, Alloy will receive up to US$27.5 million in upfront and near-term preclinical milestone payments, with potential total payments exceeding US$400 million, including milestone payments and royalties.
• Represented Biolojic Design in a multi-target drug discovery collaboration with Merck KGaA, Darmstadt, Germany, to leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders. Under the terms of the agreement, Biolojic Design will receive a low double-digit million euro upfront payment and research funding from Merck KGaA, Darmstadt, Germany, and be eligible for drug discovery, development, regulatory, and commercial milestone payments that may total up to €346 million. Biolojic Design will also be eligible to receive tiered royalties on net product sales.
• Represented Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, in its multi-year, multi-target strategic collaboration agreement with Seagen Inc. (Nasdaq: SGEN) to advance a new class of medicines called Degrader-Antibody Conjugates (DACs) for use in cancer treatment. Under the terms of the agreement, Nurix will receive an upfront payment of US$60 million and the potential to receive up to approximately US$3.4 billion in research, development, regulatory, and commercial milestone payments across multiple programs.
• Represented Keymed Biosciences, a China-based, publicly traded (Hong Kong Exchange, Stock Code: 02162) biopharmaceutical company in the out-licensing of CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC) to AstraZeneca (NASDAQ: AZN).
• Represented Akeso Inc. in a collaboration and licensing agreement with Summit Therapeutics Inc. to out-license its breakthrough bispecific antibody, ivonescimab, for development and commercialization in the U.S., Canada, Europe, and Japan. Under the terms of the agreement, Akeso will receive a US$500 million upfront payment, with a total potential deal value of up to US$5 billion. Akeso will also receive a low double-digit percentage of royalties on net product sales of ivonescimab.